Neurocrine Biosciences, Inc. (NBIX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $154.23. The rating moved from Neutral to Oversold on August 19, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$154.23
• Last changeMoved from Neutral to Oversold on August 19, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic

See all oversold Healthcare stocks →

AI analysis

Neurocrine Biosciences shows a stable commercial base complemented by pipeline programs that can drive upside if clinical milestones succeed. Near-term market dynamics—positive biotech sentiment, lower long yields and institutional flows—are supportive. Key strengths include proven commercialization capability and potential business-development optionality. Principal vulnerabilities are clinical/regulatory outcomes, payer/pricing pressure, and revenue concentration, which could rapidly shift the stock’s outlook. Over the next month the balance of fundamentals and sector momentum suggests modest upside if no adverse news emerges, while negative trial results or material payer actions would be the primary triggers for underperformance.

Key factors

• Established commercial franchise with durable revenue stream from marketed therapeutics and demonstrated commercial execution
• Pipeline assets and R&D programs that provide multi-year upside if clinical milestones are met
• Broad biotech sector momentum and institutional flows into growth names amid hopes for rate stability
• Favorable market technicals for pharma from lower long-term yields, which support valuation re-rating and M&A optionality
• Management's history of partnerships and potential business development to extend product lifecycle or broaden indication sets

Risks

• Clinical and regulatory risk: trial failures or adverse readouts could materially reduce valuation
• Pricing and payer pressure, including strategic rationalization by payers and PBMs that could limit pricing power or access
• Revenue concentration risk if one or two products represent a large portion of sales and face competition or patent challenges
• Macro and sentiment-driven volatility tied to inflation data, geopolitical headlines, or broader market risk-off moves
• Execution risk around commercialization in new indications, international launches, or manufacturing/ supply chain disruptions

Latest MarketMoodz coverage

• Arista Eyes ~43% Upside as 10 Analysts Forecast Tuesday2026-04-07

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.